Pesquisar
Vyne Therapeutics Inc
VYNEAdicionar à lista de desejos
28.560USD
0.0000.00%
Horário de mercado （ET）
110.85MValor de mercado
PerdaP/L TTM
Sobre o Vyne Therapeutics Inc Empresa
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc Perfil
Código da empresaVYNE
Nome da EmpresaVyne Therapeutics Inc
Data de listagemJan 25, 2018
CEODomzalski (David)
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 25
Endereço685 Route 202/206 N., Suite 301
CidadeBRIDGEWATER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08807
Telefone18007757936
Sitehttps://vynetherapeutics.com/
Código da empresaVYNE
Data de listagemJan 25, 2018
CEODomzalski (David)
Executivos da empresa Vyne Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
902.00
-34.15%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
592.00
-76.01%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
149.00
--
Dr. Rebecca Velez Frey, Pharm.D.
Dr. Rebecca Velez Frey, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lori Payton, Ph.D.
Dr. Lori Payton, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Rachael Alford, Ph.D.
Dr. Rachael Alford, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
902.00
-34.15%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
592.00
-76.01%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
149.00
--
Perguntas frequentes
Quem são os cinco principais acionistas de Vyne Therapeutics Inc?
Os cinco principais acionistas de Vyne Therapeutics Inc são: Mr. Tyler Zeronda
Quantas instituições possuem ações da Vyne Therapeutics Inc (VYNE)?
Em 2026Q1, 92 instituições possuíam ações da Vyne Therapeutics Inc, com valor de mercado aproximado de 11.08M, representando 33.26% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1672969.00.